Efficacité et tolérance de l’ixekizumab, anticorps...

Efficacité et tolérance de l’ixekizumab, anticorps monoclonal anti-interleukine-17A, dans le traitement du psoriasis en plaques chronique. Étude de phase II, en ouvert pendant un minimum de 52semaines

Gordon, K.B., Leonardi, C., Lebwohl, M., Cameron, G., Erickson, J., Braun, D., Banerjee, S., Augendre-Ferrante, B.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
141
Language:
french
Journal:
Annales de Dermatologie et de Vénéréologie
DOI:
10.1016/j.annder.2014.09.558
Date:
December, 2014
File:
PDF, 62 KB
french, 2014
Conversion to is in progress
Conversion to is failed